WithdrawnPhase 2NCT00005998
Peripheral Stem Cell Transplantation With Specially Treated Stem Cells in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease
Studying Epstein-Barr virus-associated malignant lymphoproliferative disorder
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Masonic Cancer Center, University of Minnesota
- Principal Investigator
- Daniel J. Weisdorf, MDMasonic Cancer Center, University of Minnesota
- Intervention
- carmustine(drug)
- Eligibility
- 18-70 years · All sexes
- Timeline
- 2000 – 2003
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00005998 on ClinicalTrials.govOther trials for Epstein-Barr virus-associated malignant lymphoproliferative disorder
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07381738Unrelated Cord Blood Transplantation for EBV-associated Lymphoproliferative DisordersFudan University
- RECRUITINGPHASE1, PHASE2NCT07450391EBV-AST Cell Injection for EBV-Associated Lymphoproliferative DisordersDaihong Liu
See all trials for Epstein-Barr virus-associated malignant lymphoproliferative disorder →